Spero Therapeutics Q3 net loss widens on SP001 licensing payment
SPRO•Spero Therapeutics reported a third-quarter net loss of $44.3 million, compared with a $27.5 million analyst consensus, as revenue fell to zero from $5.4 million a year earlier. The loss included a $35 million upfront SP001 licensing payment; the company ended the quarter with $107.9 million in cash and expects its runway to extend into the second half of 2029.
1. Quarterly results
Spero Therapeutics’ third-quarter revenue fell to zero from $5.4 million a year earlier, while its net loss widened to $44.3 million. Research and development expenses rose mainly because of a $35 million upfront payment for SP001 licensing. The company reported $41.91 million in operating expenses.
2. Cash and outlook
Spero ended the quarter with $107.9 million in cash and equivalents and expects the funds to support operations into the second half of 2029. It expects to initiate a Phase 2 study of SP001 in IgG4-RD in the second quarter of 2027 and continues to evaluate other potential indications.
